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ABSTRACT
It has been >35 years since the link between angiogen-
esis and the growth of tumors was first reported. Tar-
getingangiogenesisbecamefeasiblewiththeavailability
of bevacizumab, an anti–vascular endothelial growth
factor monoclonal antibody. Initial studies revealed
that the combination of bevacizumab and chemother-
apy led to longer overall survival times than with che-
motherapy alone in patients with advanced colorectal
cancer. Since then, drug development strategies have
added small molecule tyrosine kinase inhibitors to the
panel of antiangiogenic agents under evaluation; data
from numerous trials are now available. The challenge
now is to identify the optimal antiangiogenic agent for
specific patient groups and to understand not only the
mechanistic differences between agents, but also the
variability in their antitumor activity across different
tumortypesandtheirdifferingside-effectprofiles.Asin
other solid tumors, angiogenesis contributes to the de-
velopment of non-small cell lung cancer (NSCLC), and
this review summarizes the role of angiogenesis in this
disease. We review the current developmental status of
antiangiogenic tyrosine kinase inhibitors (including
vandetanib, sunitinib, axitinib, sorafenib, vatalanib,
and pazopanib) in NSCLC and conclude by briefly dis-
cussingtheneedforoptimalpatientselectionandpoten-
tial future directions. The Oncologist 2010;15:436–446
INTRODUCTION
Angiogenesis is a complex process that is essential for the
growth of tumors. Judah Folkman first suggested that tumor
growth was dependent on angiogenesis in 1971, predicting
that tumor size would be limited to 1–2 mm in the absence of
angiogenesis and that tumor cells secrete a protein that stimu-
lates angiogenesis [1, 2]. In order for angiogenesis to occur,
several signaling pathways must be suppressed or activated
[3].Someofthesesignalingpathways,suchasthevascularen-
dothelial growth factor (VEGF) pathway and platelet-derived
growth factor (PDGF) pathway, control the activity of blood
vessel–associated cells, including endothelial cells and peri-
cytes.
Whereas the primary stimulus for angiogenesis in the
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of hypoxia-inducible factor-1, and the subsequent activa-
tion of VEGF, numerous other growth factors and protein
productsofoncogenesandtumor-suppressorgenesarealso
involved (Table 1) [4]. As tumor-associated blood vessels
develop, cytokine-rich plasma is exuded and provides a
gradientalongwhichnewendothelialcellsmigrateandnew
capillary tubes form [5]. Under normal physiologic condi-
tions, blood vessel maturation occurs when endothelial
cells secrete PDGF, which in turn stimulates pericyte re-
cruitment. However, tumor-associated vasculature fails to
mature completely, typically as a result of the development
of hypoxic regions in the tumor that stimulate a perpetual
cycleofVEGFproduction,angiogenesis,andfurthertumor
growth[6].Becauseangiogenesisisacomplexprocessme-
diated by many factors, there are potentially multiple sig-
naling pathways involved that can be targeted by antitumor
therapies (Fig. 1). While targeting one signaling pathway
maybeeffective,targetingseveralinterconnectedsignaling
pathways may theoretically result in increased therapeutic
benefit,particularlyasthetumormayutilizealternativesig-
naling pathways as “escape” mechanisms [7]. This concept
issupportedbydatathatsuggestanadditiveeffectontumor
response when both the VEGF and PDGF signaling path-
ways are inhibited [8–10]. Preclinical research has identi-
fied several targeted antiangiogenic agents, including
monoclonal antibodies and tyrosine kinase inhibitors
(TKIs). Monoclonal antibodies prevent receptor activation
by binding directly to the ligand, whereas TKIs inhibit ki-
nase activity by competing with ATP in the tyrosine kinase
catalytic domain. This review describes the role of angio-
genesis in non-small cell lung cancer (NSCLC) and sum-
marizes some of the available data from studies of
antiangiogenic agents.
Although multitargeted TKIs are the focus of this re-
view, it is important to consider that numerous antiangio-
genic/antivascular agents with alternative mechanisms of
action are in preclinical/early clinical development. These
include aflibercept, a recombinant fusion protein that binds
all isoforms of VEGF, the combretastatins (e.g., CA-4-P),
which are tubulin-binding, vascular-disrupting agents, and
the bisphosphonates, which may reduce the incidence of
bone metastases through antiangiogenic mechanisms.
TUMOR ANGIOGENESIS
VEGF is one of the most potent mediators of tumor angio-
genesis. There are four homologues within the VEGF gene
family: VEGF-A, VEGF-B, VEGF-C, and VEGF-D.
VEGF-A is a key regulator of blood vessel development in
adult tissues, whereas VEGF-B is implicated in embryonic
angiogenesis. VEGF-C and VEGF-D are thought to be pri-
marily involved in lymphatic angiogenesis. The VEGF li-
gands bind to three VEGF receptors (VEGFRs): VEGFR-1
(alsoknownasFlt-1),VEGFR-2(alsoknownasKDR),and
VEGFR-3 (also known as Flt-4). VEGFR-2 is the primary
receptor involved in endothelial cell proliferation and mi-
gration [11].
Signaling pathways activated by PDGF are integral to
the growth and survival of vascular smooth muscle cells
and pericytes [12, 13]. There are three active forms of the
PDGFprotein:PDGF-AA,PDGF-BB,andPDGF-AB(two
other forms that require proteolytic cleavage before activa-
tion can occur are PDGF-CC and PDGF-DD). These li-
gands bind with varying affinity to the two receptor
subunits (PDGFR and PDGFR), which subsequently
dimerize to form PDGFR, PDGFR, or PDGFR.
PDGFR expression on pericytes is an essential requirement
for the survival of tumor vasculature [14].
Other factors with pro-/antiangiogenic properties in-
clude epidermal growth factor (EGF), stem cell factor, fi-
broblast growth factor (FGF), colony-stimulating factor
(CSF)-1,angiopoietin(Ang)-1/Tie-2,placentalgrowthfac-
tor, endothelin (ET)-1 and ET-2, thrombospondin, an-
giostatin, endostatin, and lactate (Table 1). EGF has been
linked to cell proliferation, apoptosis, angiogenesis, and
metastatic spread in many human carcinomas, whereas
overexpressionofwild-typeEGFreceptor(EGFR)hasalso
Table 1. Factors regulating angiogenesis
Proangiogenic factors Antiangiogenic factors
Growth factors
VEGF, FGF, EGF, TGF-,























Abbreviations: COX, cyclo-oxygenase; EGF, endothelial
growth factor; ET, endothelin; FGF, fibroblast growth
factor; IFN, interferon; IL, interleukin; MCP, monocyte
chemoattractant protein; NOS, nitric oxide synthase;
PDGF, platelet-derived growth factor; PIGF, placental
growth factor; TGF, transforming growth factor; TNF,
tumor necrosis factor; VEGF, vascular endothelial growth
factor.
Adapted from Herbst RS, Onn A, Sandler A.
Angiogenesis and lung cancer: Prognostic and therapeutic
implications. J Clin Oncol 2005;23:3243–3256.
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nosis in NSCLC [15, 16].
Although angiogenesis is the primary mechanism by
which tumors coopt a blood supply, other methods are also
used. These methods include intussusceptive microvas-
cular growth, vasculogenesis via the recruitment of
bloodborne endothelial progenitor cells, glomeruloid an-
giogenesis,andvasculogenicmimicry[3,7].Angiogenesis,
as measured using microvessel density (MVD), can be a
predictorofpoorsurvivalinavarietyofneoplasms,includ-
ing NSCLC [17, 18]. Studies have also shown that levels of
VEGF (and PDGF) correlate significantly with increased
angiogenesis,poorprognosis,andlymphnodemetastasisin
patients with NSCLC [8, 17–20]. Indeed, high levels of
VEGF have been linked to shorter survival in patients with
NSCLCwhoreceivedtheVEGFRandEGFRinhibitorvan-
detanib [21, 22]. Furthermore, an immunohistochemical
study of NSCLC tumor specimens found that MVD was
higher in samples from patients with advanced-stage than
thosewithearly-stageNSCLC,anditwasalsohigherinpa-
tientswithlymphnodemetastasesthaninthosewithnome-
tastases [23]. This same study also hypothesized that high
levels of the antiangiogenic factor thrombospondin-1 may
delay disease progression [23].
STANDARDS OF CARE FOR THE SYSTEMIC
TREATMENT OF ADVANCED NSCLC
Approximately219,000newlungcancercasesand160,000
deaths were estimated to have occurred in the U.S. in 2009
[24]. Most patients with lung cancer present with advanced
disease and, globally, platinum-based doublet chemother-
apy remains the standard of care for patients with a good
performance status [25]. Although numerous systemic che-
motherapy doublets and triplets have been studied, they
produce similar outcomes. However, promising data have
been reported with the folate antimetabolite, pemetrexed
(Alimta ;EliLillyandCompany,Indianapolis,Indiana),in
both a first-line setting [26] and as maintenance therapy
[27].First-linecisplatinpluspemetrexedwasnoninferiorto
cisplatin plus gemcitabine, although a significant survival
advantage with cisplatin plus pemetrexed was observed in
patients with adenocarcinoma or large-cell carcinoma [26].
Based on maintenance data revealing that pemetrexed dou-
bled the time to disease progression, compared with pla-
cebo (4.04 months versus 1.97 months), in July 2009
pemetrexed was approved in the U.S. and European Union
as maintenance therapy in NSCLC patients with nonsqua-
mous histology [27].
Clinical research efforts with targeted agents have en-
deavored to improve survival beyond that provided by che-
motherapy. Two pivotal phase III trials provide the
foundation for using targeted antiangiogenic agents in
NSCLC. The Eastern Cooperative Oncology Group
(ECOG) 4599 trial randomized patients with advanced
nonsquamousNSCLCtoreceivepaclitaxelandcarboplatin
with or without the anti-VEGF monoclonal antibody bev-
acizumab (Avastin ; Genentech, San Francisco, CA), or
placebo.Thatstudyreportedamedianoverallsurvival(OS)
time of 12.3 months with the addition of bevacizumab to
chemotherapy, and only 10.3 months with chemotherapy
alone[28].ThestudyestablishedthattheVEGFpathwayis
a valid target for therapy. Subsequently, a second phase III
European trial, AVAstin in Lung (AVAiL), assessed bev-
acizumab (7.5 mg/kg and 15 mg/kg) in combination with
cisplatin and gemcitabine in chemotherapy-naïve patients
with advanced or recurrent NSCLC. That study demon-
strated a higher objective response rate (ORR) and longer
progression-free survival (PFS) time with both doses of be-
vacizumab; the ORRs were 20.1 months (placebo), 34.1
months (7.5 mg/kg), and 30.4 months (15 mg/kg). The me-
dian PFS time was significant for the 7.5 mg/kg dose level
(6.5 months versus 6.1 months; p  .003). No statistically
significant improvement in OS was observed. The reason
for a lack of survival benefit is unclear, with proposed rea-
sonsincludingpoststudytreatment,apotentiallysmalleref-
fect size of bevacizumab when combined with more
effective chemotherapy, and statistical power [29].
COMBINATION THERAPY:T ARGETING VEGF
AND EGFR
Combining an antiangiogenic, single-target agent and a
chemotherapeutic agent has resulted in proven activity
across multiple tumor types; however, the future of cancer
treatment may lie with the development of drugs or drug
combinations that are directed against multiple tumor tar-
gets. Inhibition of multiple targets could be achieved with a
single agent or with a combination of agents. In NSCLC,
preclinical data in xenograft models have identified the
VEGFR and EGFR pathways as rational therapeutic tar-
gets;inhibitionoftumorgrowthwasmostpronouncedwith
the combination of bevacizumab and the anti-EGFR TKI
erlotinib (Tarceva ; Genentech, Inc., South San Francisco,
CA) than with either agent alone [30]. The anti-EGFR
monoclonal antibody cetuximab (Erbitux ; Merck Serono,
Darmstadt, Germany) has shown promising antitumor ac-
tivity in NSCLC and was studied in combination with bev-
acizumab plus chemotherapy in a phase II Southwest
OncologyGroup(SWOG)trial.Thetreatmentcombination
was tolerable and evidence of antitumor activity was re-
ported in a presentation at the annual meeting of the Amer-
ican Society for Clinical Oncology (ASCO) in 2009 [31].
A phase I/II study of erlotinib plus bevacizumab en-
438 Antiangiogenic Agents in NSCLCrolled patients with pretreated nonsquamous, advanced
NSCLC.ThemedianOStimewas12.6monthsandthePFS
durationwas6.2months[32].ResultsfromanotherphaseII
study in pretreated patients again supported further study
with this treatment combination; bevacizumab plus erlo-
tinib achieved activity comparable with that of bevaci-
zumab plus chemotherapy (median OS time, 13.7 months
for bevacizumab plus erlotinib versus 12.6 months for be-
vacizumab plus chemotherapy) [33]. Consequently, this
combination was studied in the phase III BeTa Lung trial in
pretreated patients with advanced NSCLC. Unfortunately,
theprimaryendpointofalongerOStimethanwitherlotinib
alone was not met (median OS time, 9.3 months versus 9.2
months; p  .75; hazard ratio [HR], 0.97) [34].
More recently, other trials have been presented, includ-
ing the phase III ATLAS trial (investigating bevacizumab
and erlotinib versus bevacizumab plus placebo, as mainte-
nance therapy following first-line treatment) [35]. That
studywasstoppedearlyontherecommendationofaninde-
pendent data safety monitoring committee after a pre-
plannedinterimanalysisthatshowedthecombinationledto
a significantly longer PFS interval than with bevacizumab
plus placebo.
MULTITARGETED AGENTS
Efforts to identify drugs that inhibit key pathways in-
volved in the pathogenesis of cancer have led to the de-
velopment of multitargeted agents. Small-molecule
TKIs that inhibit receptors such as VEGFR, PDGFR,
Raf, and KIT simultaneously may offer advantages over
agents with single targets, and therefore a higher likeli-
hood of single-agent activity. In addition, because mul-
titargeted TKIs are often available orally, they may be
more convenient for patients. Conversely, a potential
disadvantage is the potential for toxicity resulting from
off-target kinase inhibition, and the additive toxicity that
may be particularly relevant when the agents are com-
bined with chemotherapy.
Several multitargeted, antiangiogenic agents have been
studied in clinical trials. Most of these agents inhibit
VEGFR, and some also inhibit PDGFR, Raf, and EGFR
(Table 2). Clinical experience with these compounds is de-
scribed below. Those currently being investigated in phase
III trials are summarized in Table 3.
Vandetanib
Vandetanib (Zactima , ZD6474; AstraZeneca Pharmaceu-
ticals, Wilmington, DE) is a VEGFR and EGFR inhibitor,
although the difference in the 50% inhibitory concentration
for these two targets translates into more potent inhibition
of VEGFR than EGFR at pharmacologically achievable
doses. In a phase II trial, vandetanib in combination with
carboplatin and paclitaxel led to a higher ORR and longer
PFS time (primary endpoint) but no difference in OS when
compared with vandetanib alone in chemotherapy-naïve
patients with NSCLC [36]. Higher incidences of rash, diar-
rhea, asymptomatic QTc-related events, and hypertension
were observed in the vandetanib arm. The study allowed
enrollment of patients with central nervous system (CNS)
metastases and all NSCLC histologies; patients who en-
tered with CNS metastases or squamous histology did not
experienceintracranialbleedingorhemoptysisofgrade2
[36]. The vandetanib-alone arm was stopped early after an
interim analysis met the criterion for discontinuation. Van-
detanib plus docetaxel was shown to be superior to do-
cetaxel alone in pretreated patients with advanced NSCLC,
and vandetanib led to a significantly longer PFS time than
with gefitinib, again in a second-line setting [37, 38]. Sub-
sequently, an extensive phase III program has been con-
ducted: ZODIAC (vandetanib plus docetaxel versus
Table 2. Antiangiogenic tyrosine kinase receptor inhibitors and their targets
Agent VEGFR-1 VEGFR-2 VEGFR-3 PDGFR EGFR Other targets
Vandetanib ●● RET
Sunitinib ●●●● KIT, FLT3, RET
Axitinib ●●●
Sorafenib ●●●● KIT, RAF, FLT3
Vatalanib ●●●● KIT
Cediranib ●●●● KIT
Motesanib ●●●● KIT, RET
Pazopanib ●●●● KIT
BIBF 1120 ●● FGFR
Abbreviations: FGFR, fibroblast-like growth factor receptor; FLT3, FMS-like tyrosine kinase 3; KIT, stem cell factor
receptor; RET, glial cell line-derived neurotrophic factor receptor; VEGFR, vascular endothelial growth factor receptor.
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versuspemetrexedalone)arebothplacebo-controlled,dou-
ble-blind, randomized studies evaluating the efficacy of
vandetanib in second-line advanced NSCLC. Data pre-
sented at the 2009 ASCO Annual Meeting revealed accept-
able safety profiles and significant improvements in
response in both studies versus chemotherapy alone. Simi-
larly, improvements in the primary endpoint (PFS versus
chemotherapy alone) were reported but statistical signifi-
cance was reached only in ZODIAC (PFS for vandetanib
plus docetaxel was 4 months versus 3.2 months for do-
cetaxel alone; HR, 0.79; 95% confidence interval [CI],
0.70–0.90, p  .001) [39, 40]. However, whether a 3-week
improvement in PFS is clinically meaningful remains to be
determined. ZEST is a phase III head-to-head comparison
of vandetanib versus erlotinib. Again, based on data re-
portedatthe2009ASCOAnnualMeeting,theprimaryend-
point of PFS was not met (vandetanib, 11.3 weeks versus
erlotinib, 8.9 weeks; HR, 0.98; 95% CI, 0.87–1.10; p 
.721) [41]. Finally, ZEPHYR is a randomized, double-
blind phase III study of vandetanib plus best supportive
careversusbestsupportivecarealoneinpatientswithad-
vanced NSCLC after failure of prior treatment with an
anti-EGFR TKI, and results are expected in 2010. Based
on these data, the role of vandetanib in NSCLC remains
somewhat uncertain; the initial results are frankly some-
what disappointing.
Sunitinib
Sunitinib (Sutent , SU11248; Pfizer Inc., New York) is an
inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFRs,
KIT, FLT3, RET, and CSF-1R, and is approved multina-
tionally for the treatment of advanced renal cell carcinoma
(RCC) and imatinib-resistant or imatinib-intolerant gastro-
intestinalstromaltumor.Theantitumoractivityofsunitinib
in NSCLC is supported by preclinical data derived from in
vivomodels.Combinationtreatmentwithsunitinibplusdo-
cetaxel, pemetrexed, gemcitabine, or platinum agents re-
sulted in significantly greater tumor growth inhibition than
with sunitinib alone [42]. In a phase II trial, in which
sunitinib was administered on a continuous daily dosing
(CDD) schedule in patients with previously treated
NSCLC, the median PFS time was 11.9 weeks (95% CI,
8.6–14.1weeks),themedianOStimewas37.1weeks(95%
CI, 24.2–52.5), and treatment was generally well tolerated;
most adverse events were grade 1 or 2 [43]. An earlier pa-
Table 3. Active phase III trials of antiangiogenic multitargeted tyrosine kinase inhibitors in advanced NSCLC
Agent Design Target enrollment (n) Primary endpoint
Sunitinib (Sutent ) Sunitinib  erlotinib versus erlotinib second/
third line; NCT00457392 (SUN1087)
956 OS
Sunitinib as maintenance therapy in




Sorafenib (Nexavar ) Gemcitabine  cisplatin  sorafenib versus
gemcitabine  cisplatin  placebo first-line;
NCT00449033 (NEXUS)
350 PFS
Sorafenib with or without placebo third/fourth
line in patients with predominantly
nonsquamous histology; NCT00863746
850 OS
Vandetanib (Zactima ) Vandetanib  BSC versus BSC after therapy
with an EGFR TKI; NCT00404924 (ZEPHYR)
930 OS
Motesanib Motesanib  paclitaxel  carboplatin
(MONET1); NCT00460317
1,400 OS
BIBF 1120 (Vargatef ) BIBF 1120  pemetrexed versus placebo 
pemetrexed second line in patients with
nonsquamous histology; NCT00806819 (LUME
Lung 2)
1,302 PFS
BIBF 1120  docetaxel versus placebo 
docetaxel second line; NCT00805194 (LUME
Lung 1)
1,306 PFS
Information on ongoing phase III trials was obtained from http://www.clinicaltrials.gov (accessed December 2009) using
the name of the TKI and “lung” as search criteria.
Abbreviations: BSC, best supportive care; CALGB, Cancer and Leukemia Group B; EGFR, epidermal growth factor
receptor; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.
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Schedule 4/2 (4 weeks on treatment followed by 2 weeks
off treatment); again, treatment appeared active with a me-
dian PFS duration of 12.0 weeks (95% CI, 10.0–16.1
weeks) and a median OS time of 23.4 weeks [44]. Sunitinib
was well tolerated, with most adverse events being grade 1
or 2. Responses were also observed in a phase I study of
sunitinib plus gemcitabine and cisplatin [45]. Ongoing tri-
als of sunitinib in advanced, platinum-refractory NSCLC
include SUN1058 and SUN1087 (Table 3). SUN1058 is a
phaseIItrialinvestigatingsunitinib(37.5mg)pluserlotinib
(150 mg) on a CDD schedule; patients are stratified based
on smoking history and EGFR status. SUN1087 is a phase
III trial of sunitinib (37.5 mg) and erlotinib (150 mg), again
onaCDDschedule,andemploysthesamestratificationcri-
teria in addition to stratification based on prior treatment
with bevacizumab. By targeting EGFR as well as VEGFR




activity against all three VEGFRs (VEGFR-1, VEGFR-2,
andVEGFR-3)atclinicaldosesandiscurrentlybeingstud-
ied in multiple solid tumor settings [46]. In a phase II study
ofpatientswithadvancedNSCLCtreatedwithsingle-agent
axitinib (in the first-line, second-line, or third-line setting),
the median PFS interval was 4.9 months overall (95% CI,
3.6–7.0 months), and the median OS time of 14.6 months
was greater than expected in such a mixed patient popula-
tion [47]. Treatment was also well tolerated. Ongoing trials
of this agent in nonsquamous NSCLC patients include the
phaseIIAGILE1030trial(axitinibpluspaclitaxelpluscar-
boplatin versus bevacizumab plus paclitaxel plus carbopla-
tin), the phase II AGILE 1039 trial (axitinib plus cisplatin
and pemetrexed versus cisplatin and pemetrexed), and the
phase II AGILE 1038 trial in squamous cell carcinoma (ax-
itinib plus cisplatin and gemcitabine).
Sorafenib
Sorafenib (Nexavar , BAY 43–9006; Bayer Pharmaceuti-
cals Corporation, West Haven, CT) is a Raf and VEGFR
inhibitor (VEGFR-2 and VEGFR-3) with activity against
PDGFR and KIT. It is licensed in many countries for the
treatment of advanced RCC and hepatocellular carcinoma
[48]. In xenograft models, sorafenib plus vinorelbine, cis-
platin, or gefitinib resulted in tumor growth delay at least
comparable with that observed with each agent alone [49].
In the phase III ESCAPE trial (carboplatin plus paclitaxel,
withandwithoutsorafenibinfirst-line,advancedNSCLC),
the primary endpoint of OS was not met and the study was
terminated early as a result of the detrimental effect of sor-
afenib on patients with squamous cell carcinoma and the
lack of effect in the population with nonsquamous cell car-
Figure 1. Pathways blocked by tyrosine kinase inhibitors and monoclonal antibodies.
Abbreviations: EGF, endothelial growth factor; EGFR, endothelial growth factor receptor; GRB2, growth factor receptor-
bound protein-2; MAPK, mitogen-activated protein kinase; MEK, MAPK/extracellular signal–related kinase kinase; PI3K, phos-
phoinositide 3-kinase; PDGF, platelet-derived growth factor; PTEN, phosphatase and tensin homologue deleted on chromosome
ten; SOS, son of sevenless; STAT, signal transducer and activator of transcription; VEGF, vascular endothelial growth factor;
VEGFR, vascular endothelial growth factor receptor.
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fourth-line treatment setting is currently under consider-
ation [50]. Data from a phase II trial of heavily pretreated
patients with advanced NSCLC revealed a statistically sig-
nificant higher number of patients with stable disease at 2
months with sorafenib (sorafenib, 47% versus placebo,
19%; p  .01), and toxicities were manageable [51]. Sin-
gle-agent sorafenib showed disease stabilization in 59% of
51NSCLCpatientsinaphaseIItrial,withanOStimeof6.8
months and a median PFS time of 2.8 months [52].
Vatalanib
Vatalanib (PTK787; Novartis/Schering AG, Berlin, Ger-
many) is a VEGFR, PDGFR, and KIT inhibitor that is cur-
rently being studied in phase II/III trials. Data from a phase
II trial examining vatalanib monotherapy administered
once or twice daily in previously treated patients with
NSCLC have been reported [53]. Single-agent treatment
appeared active, with a trend toward greater efficacy with
twice-daily treatment (11% of evaluable patients had a par-
tial response in this cohort). Additionally, treatment was
well tolerated, with no apparent differences between once-
and twice-daily dosing.
Cediranib
Cediranib (Recentin , AZD2171; AstraZeneca Pharma-
ceuticals, Wilmington, DE) is a potent VEGFR-2 inhibitor
that also inhibits VEGFR-1, VEGFR-3, and PDGFR [54].
Initial phase I data with cediranib (30 mg) in combination
with cisplatin and gemcitabine was promising in patients
with previously untreated NSCLC [55]. Toxicities, includ-
ing hypertension, fatigue, and diarrhea, were manageable
and predictable, with the maximum-tolerated dose not
reached. Given that the 30-mg dose was better tolerated
than the 45-mg dose in the phase I trial, the 30-mg dose of
cediranib was selected for combination with carboplatin
andpaclitaxelinthefirst-lineBR24phaseII/IIIstudyinpa-
tients with NSCLC. In early 2008, AstraZeneca reported
that the study would not continue into phase III following
the planned end of phase II efficacy and tolerability analy-
ses. According to the study’s data safety monitoring com-
mittee, although evidence of clinical activity was observed,
there appeared to be an imbalance in toxicity between the
treatment and control arms, and therefore the study was
considered not to have met the predefined criteria for con-
tinuation into phase III [56]. A retrospective analysis re-
vealed a higher risk for weight loss, hypoalbuminemia, and
grade 5 adverse events in patients receiving cediranib (30
mg) plus chemotherapy than in those receiving chemother-
apyalone.However,despitethesesafetydata,cediranib(30
mg) plus chemotherapy led to a higher response rate and
longer PFS time than with chemotherapy alone [56]. Con-
sequently, a reduced dose of cediranib (20 mg) plus carbo-
platin and paclitaxel will be investigated in a randomized
trial in patients with a good performance status, no signifi-
cant weight loss, and no hypoalbuminemia.
Motesanib
Motesanib (AMG 706; Amgen, Thousand Oaks, CA) is a
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, KIT, and RET
inhibitor that is currently in clinical development in multi-
ple tumor types, including NSCLC. Phase I data have
shown that motesanib can be combined safely with pacli-
taxel plus carboplatin and/or panitumumab, an anti-EGFR
monoclonal antibody, in patients with advanced NSCLC
[57]. Treatment-related adverse events in that study were
generally mild to moderate, with fatigue and hypertension
being the most common grade 3 adverse events [57]. A
phase III trial investigating motesanib (125 mg daily) in
combination with paclitaxel and carboplatin was tempo-
rarilysuspendedinNovember2008becauseofahigherrisk
for hemoptysis in patients with squamous cell histology.
These patients were discontinued and the study was re-
started; patients with nonsquamous cell histology (approx-
imately two thirds of the original study population) are
continuingontreatment,andpatientswiththishistologyare
continuing to be enrolled (Table 3).
Pazopanib
Pazopanib (GW786034; GlaxoSmithKline, Philadelphia)
is a VEGFR, PDGFR, and KIT inhibitor currently in phase
III development for advanced RCC and in phase II devel-
opment in advanced NSCLC. Initial data from a phase II
trial in early (stage I/II) NSCLC have been presented; 87%
of patients (n  20) had a reduction in tumor volume, and
the tolerability profile in this setting was favorable [58].
NumerousphaseIIstudiesofpazopanibinpatientswithad-
vancedNSCLChaveeitherbeencompletedorareongoing,
and data are keenly awaited. These include pazopanib as
monotherapy, as well as combination studies with pacli-
taxel and pemetrexed. In addition, a phase II study of erlo-
tinib plus pazopanib versus erlotinib plus placebo is
planned[59].Antitumoractivityinthefirst-linesettingwas
observed in patients with malignant pleural mesothelioma.
A phase II study revealed a PFS duration of 5.9 months
(95% CI, 3.1–8.4 months) and OS time of 14.4 months
(95% CI, 7.2 to not achieved) [60].
BIBF 1120
BIBF 1120 (Vargatef™; Boehringer-Ingelheim, In-
gelheim, Germany) is an oral indolinone derivative that in-
hibits VEGFR-2, FGFR, and PDGFR. Phase I data in
442 Antiangiogenic Agents in NSCLCpatientswithadvancedsolidtumorsestablishedthephaseII
dose to be 200 mg twice daily and revealed that the ob-
served toxicities at this dose were manageable. Adverse
events judged to be related to treatment were most often
gastrointestinal, and there were responses in patients (three
of 23) with RCC and colorectal cancer [61]. Results from a
phase II trial of BIBF 1120 involving patients with ad-
vanced NSCLC were reported at the 13th World Confer-
ence on Lung Cancer [62]. This double-blind multicenter
trial included patients with an ECOG performance status
scoreof0–2whohadrelapsedfollowingthefailureoffirst-
or second-line chemotherapy. Again, adverse events were
most often gastrointestinal; the most common grade 1–3
toxicities were vomiting, nausea, diarrhea, anorexia, and
abdominal pain [62]. The median OS time was 264 days
[63]. Phase III trials of BIBF 1120 in advanced NSCLC are
under way—LUME Lung 1 and LUME Lung 2 (Table 3).
CHALLENGES FACING THE EFFECTIVE TREATMENT
OF NSCLC
Toxicity
The TKIs described above all inhibit multiple receptors,
thereforeinfluencingmultiplesignalingpathwaysandtheir
respectivedownstreamsignalingmolecules.Consequently,
the antitumor activity of these agents may be superior to
thatofagentswithsingletargets;however,thismustbebal-
anced against the potential for additive toxicity. For exam-
ple, inhibition of KIT has been associated with changes in
skin and hair pigmentation, whereas inhibition of VEGFRs
can lead to hypertension, hemorrhage, skin toxicity, fa-
tigue, hand–foot syndrome, and hypothyroidism (also
linked to inhibition of RET) [64–66]. Interestingly, some
studies have suggested that hypertension may actually be a
predictor of response in a variety of tumor types following
treatment with multitargeted TKIs [67]. Furthermore, inhi-
bition of PDGFR has been linked to cardiotoxicity (possi-
bly as a result of the expression of PDGFR on
cardiomyocytes), skin reactions, and edema.
Treatment with multitargeted TKIs may be associated
with off-target kinase activities resulting in possibly unex-
pected side effects, for example, cardiac-related events
[68]. Toxicities associated with the pharmacological action
of antiangiogenic TKIs, so called “class-effect” toxicities,
have also been reported, such as hypertension, hand–foot
syndrome, and impaired wound healing [69, 70]. It is be-
coming increasingly clear that a comprehensive under-
standingofthespectrumofeffectsexertedbyallanticancer
agents, including multitargeted TKIs, is fundamental for
understanding the efficacy and safety profiles of targeted
agents. While most toxicities associated with TKIs are
manageable,patientsshouldcontinuetobemonitoredcare-
fully for evidence of toxicity, particularly because pro-
longed periods of therapy may be required and side effects
may impact treatment compliance.
Combining Targeted Agents
As discussed earlier, combining targeted agents is a valid
strategy and is one that is being pursued in numerous trials
(e.g., the SUN1087 trial). It is conceivable that such regi-
mens may avoid the adverse effects commonly associated
with chemotherapy, while providing comparable and pos-
sibly superior antitumor activity. The safety and efficacy
data from the ATLAS study were recently presented. Al-
thoughnounexpectedsafetysignalswereobserved,grade3
or 4 rash and diarrhea were more common in the erlotinib
plus bevacizumab arm than in the bevacizumab plus pla-
cebo arm (10.4% versus 0.5% and 9.3% versus 0.8%, re-
spectively) [35]. Based on the statistically significant
longer median PFS time (the primary endpoint) of 4.8
months for the erlotinib plus bevacizumab arm, versus 3.7
months for the bevacizumab plus placebo arm (HR, 0.72;
95% CI, 0.59–0.88; p  .0012), that trial met its primary
endpoint and was terminated early.
Biomarkers of Response
The effective use of VEGFR TKIs will depend on identify-
ing patients who are most likely to benefit from therapy. A
number of translational medicine biomarkers are being ex-
plored to identify predictors of response and/or toxicity
based on a variety of parameters, such as tumor histology
and pretreatment levels of angiogenic molecules such as
VEGF and PDGF, levels of tumor-associated blood vessels
(MVD),KRASmutations,andlevelsofcirculatingendothe-
lial cells (CECs). An in vitro profiling study reported at the
ASCO–National Cancer Institute–European Organization
for Research and Treatment of Cancer meeting demon-
strated distinct patterns of protein secretion in response to
certain treatment regimens [71]. Furthermore, evidence
suggests a correlation between levels of some VEGF iso-
forms and survival in NSCLC patients [72, 73], with a par-
ticularly high correlation between levels of soluble
VEGFR-2 and tumor shrinkage in response to pazopanib
[74]. However, there are conflicting reports regarding the
effectiveness of using pretreatment VEGF levels as a pre-
dictive biomarker, and it is possible that it is actually bio-
available, rather than circulating, VEGF that is the most
effective predictor [75]. Similarly, high expression of
PDGF-B and PDGFR have been linked to poor outcome
in tumor cells derived from patients with stage I–III
NSCLC [76]. High MVD has been linked to poor survival
and tumor progression in NSCLC patients, and it has a par-
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metastases [77]. In addition, it is hypothesized that treating
patients with antiangiogenic agents may dissociate endo-
thelial cells from the tumor vasculature, therefore increas-
ing the number of CECs in patients’ blood. High levels of
CECs may indicate that a patient is responding to treatment
with an antiangiogenic agent, a theory with some preclini-
calsupport[78].Insummary,whileeffortsareunderwayto
identify biomarkers predictive of response to antiangio-
genic therapy, so far no single marker or set of markers
seems ready for routine clinical use.
SUMMARY
Angiogenesis is a complex process that is essential for the
growth of tumors. Initial clinical data have shown modest
efficacy when single-target agents are combined with che-
motherapy. Multitargeted antiangiogenic agents may pro-
vide advantages over agents with single targets; however,
the use of one strategy over another will rely on optimizing
the benefit–risk ratio of targeted agents, using clinical and
translationalmedicinebiomarkercharacteristicsofindivid-
ualpatients.Furtherexplorationofmultitargetedangiogen-
esis inhibitors may offer additional clinical benefits and
maypavethewaytowardthedevelopmentofrationalcom-
binations of targeted agents for NSCLC. Because similar
efficacy outcomes are being achieved with conventional
chemotherapy agents, it is conceivable that chemotherapy
regimens have reached a plateau in terms of efficacy, pos-
sibly because of the development of resistance [72, 79]. In
addition, there is continuing debate over the efficacy and
safety profiles of platinum- versus nonplatinum-based che-
motherapy regimens, particularly when considering the po-
tential toxicity concerns with platinum-based agents. As
with all treatments, the advantages obtained in terms of ac-
tivity must be weighed against the potential for greater
treatment-related toxicity.
Ultimately, personalizing anticancer therapy through
the use of biomarkers may improve the response to treat-
ment. In addition, identifying the most effective treatment
combinations, doses, and schedules may also help to im-
proveresponserates.Itisconceivablethatinhibitingangio-
genesis may become a cornerstone of NSCLC treatment in
the future.
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